Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.
Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Rose S, Jim On S, Li X, Fuentes-Duculan J, Estrada Y, Garcet S, Traidl-Hoffmann C, Krueger JG, Lebwohl MG. Guttman-Yassky E, et al. Among authors: gilleaudeau p. J Am Acad Dermatol. 2018 May;78(5):872-881.e6. doi: 10.1016/j.jaad.2018.01.016. Epub 2018 Jan 17. J Am Acad Dermatol. 2018. PMID: 29353025 Free PMC article. Clinical Trial.
A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis.
Brunner PM, Khattri S, Garcet S, Finney R, Oliva M, Dutt R, Fuentes-Duculan J, Zheng X, Li X, Bonifacio KM, Kunjravia N, Coats I, Cueto I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Brunner PM, et al. Among authors: gilleaudeau p. J Allergy Clin Immunol. 2016 Jul;138(1):169-178. doi: 10.1016/j.jaci.2015.12.1323. Epub 2016 Mar 2. J Allergy Clin Immunol. 2016. PMID: 26948076
Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis.
Khattri S, Brunner PM, Garcet S, Finney R, Cohen SR, Oliva M, Dutt R, Fuentes-Duculan J, Zheng X, Li X, Bonifacio KM, Kunjravia N, Coats I, Cueto I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Khattri S, et al. Among authors: gilleaudeau p. Exp Dermatol. 2017 Jan;26(1):28-35. doi: 10.1111/exd.13112. Epub 2016 Aug 9. Exp Dermatol. 2017. PMID: 27304428 Free PMC article. Clinical Trial.
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab.
Brunner PM, Pavel AB, Khattri S, Leonard A, Malik K, Rose S, Jim On S, Vekaria AS, Traidl-Hoffmann C, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Fuentes-Duculan J, Li X, Zheng X, Estrada Y, Garcet S, Wen HC, Gonzalez J, Coats I, Cueto I, Neumann AU, Lebwohl MG, Krueger JG, Guttman-Yassky E. Brunner PM, et al. Among authors: gilleaudeau p. J Allergy Clin Immunol. 2019 Jan;143(1):142-154. doi: 10.1016/j.jaci.2018.07.028. Epub 2018 Aug 17. J Allergy Clin Immunol. 2019. PMID: 30121291 Clinical Trial.
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
Guttman-Yassky E, Renert-Yuval Y, Bares J, Chima M, Hawkes JE, Gilleaudeau P, Sullivan-Whalen M, Singer GK, Garcet S, Pavel AB, Lebwohl MG, Krueger JG. Guttman-Yassky E, et al. Among authors: gilleaudeau p. Allergy. 2022 Mar;77(3):897-906. doi: 10.1111/all.15071. Epub 2021 Sep 6. Allergy. 2022. PMID: 34460948 Free PMC article. Clinical Trial.
Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology.
Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, Gilleaudeau P, Sullivan-Whalen M, Zheng X, Xu H, Cardinale I, de Guzman Strong C, Gonzalez J, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Khattri S, et al. Among authors: gilleaudeau p. J Allergy Clin Immunol. 2014 Jun;133(6):1626-34. doi: 10.1016/j.jaci.2014.03.003. Epub 2014 Apr 29. J Allergy Clin Immunol. 2014. PMID: 24786238 Free PMC article.
Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence.
Rozenblit M, Suarez-Farinas M, Shemer A, Khattri S, Gilleaudeau P, Sullivan-Whalen M, Zheng X, Xu H, Cardinale I, Krueger JG, Guttman-Yassky E. Rozenblit M, et al. Among authors: gilleaudeau p. J Allergy Clin Immunol. 2014 Oct;134(4):955-7. doi: 10.1016/j.jaci.2014.05.024. Epub 2014 Jul 2. J Allergy Clin Immunol. 2014. PMID: 24996261 Free PMC article. No abstract available.
Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population.
Czarnowicki T, Gonzalez J, Shemer A, Malajian D, Xu H, Zheng X, Khattri S, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Czarnowicki T, et al. Among authors: gilleaudeau p. J Allergy Clin Immunol. 2015 Jul;136(1):104-115.e7. doi: 10.1016/j.jaci.2015.01.020. Epub 2015 Mar 3. J Allergy Clin Immunol. 2015. PMID: 25748064
54 results